-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biology company Mustang recently announced that the first patient has been treated with drugs in a multi-center Phase I/II clinical trial to evaluate MB-102 (CAR-T cell therapy for CD123) to treat recurring recurring recurring recurring resuscious maternal plasma cell-like dendioblast tumors (BPDCN), acute myeloid leukemia (AML) and high-risk myeloid proliferative syndrome (hrMDS).
sites include City of Hope, Dana Faber Cancer Institute, Duke University and MD Anderson Cancer Center.
MB-102 is a CAR-T cell therapy that identifies and eliminates tumors that express CD123 by transforming patient T-cells.
CD123 is widely expressed in bone marrow cells in patients with bone marrow hyperploid syndrome, as well as in blood system malignancies, including AML and BPDCN.
the first phase of the trial will determine the maximum to-dosage of MB-102 for the second phase of the trial.
safety will be assessed at each dose level before the next dose is carried out.
end of the study was the mitigation rate on the 28th day after infusion in all groups, and the secondary endpoint included reaction duration, no progression lifetime, overall lifetime, and the occurrence of adverse events.
.
